Urology treatment studies show increased reporting of harmful effects

Newswise — Waltham — December 11, 2023 —  

In recent years, clinical trial reports in major urology journals have been more likely to include data on harmful effects of treatments, reports a study in the January issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer. 

"Our analysis finds a marked increase in reporting of potential harms in randomized treatment trials published in top-ranked urology journals," comments lead author Reece M. Anderson, MPH, Medical Student Researcher at Oklahoma State University Center for Health Sciences, Tulsa. "This information will help to improve informed decision-making about urology treatments, and contribute to improving the quality of urology research." 

Urology RCTs are meeting more criteria for harms reporting... 

Randomized controlled trials (RCTs) provide the highest quality of evidence for evaluating medical treatments. In addition to evidence of treatment effectiveness, RCTs should include a "balanced, transparent, and unbiased appraisal" of any harmful effects, according to the authors. 

However, in urology as in other specialties, published studies often fail to provide adequate data on harms. In 2004, the CONSORT group created a "harms-specific reporting guideline," with the aim of improving transparency of RCTs. A 2010 paper in The Journal of Urology found "significant deficiencies" in reporting of adverse effects in urology treatments. 

Has reporting of harms increased in more recent years? To find out, Mr. Anderson and colleagues analyzed 132 papers published in four leading journals  – The Journal of Urology, Urology, European Urology, and BJU International – in 2012 or 2020.  

Following a standardized method, the researchers evaluated how well the studies followed the CONSORT harms reporting guidelines. Harms were defined as "any undesirable consequences" of treatment, including adverse events, side effects, complications, toxicity, or other conditions interfering with patient safety or satisfaction. 

During the period studied, reporting of harms in urology RCTs increased significantly. The median number of harms criteria addressed increased from 5.3 in papers published in 2012 to 7.2 in 2020. Papers published in 2020 reported more than three-fourths of items suggested by the CONSORT guidelines. That contrasts with the study from 2010, when only about one-third of items were addressed.  

...But more progress needed to meet 'standards of transparency and accuracy' 

Improvements in the methods used to evaluate harmful effects included which harms were assessed, when the information was collected, and how the harms were attributed to the study treatments. Results criteria improved as well, including gains in reporting the reasons for patient withdrawals, the effect size of the reported harms, and the distinction between serious and minor harms. 

But while the results show "marked improvement in completeness of reporting, key deficits still exist," the researchers write. They suggests steps that researchers and medical journals can take toward further improvement, including checklists addressing each of the CONSORT harms criteria.  

"Complete reporting of harms is crucial for ensuring that readers have a comprehensive understanding of the safety and effectiveness of interventions," Mr. Anderson and coauthors conclude. They emphasize the need "for ongoing efforts to ensure that harms reporting meets the highest standards of transparency and accuracy." 

Read Article [ Urology treatment studies show increased reporting of harmful effects ] 

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health. 

### 

About The Journal of Urology® 

The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology. 

About the American Urological Association 

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org 

About Wolters Kluwer  

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.  

Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.  

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, and YouTube.